Home / Market News / $RVMD
benzinga Corporate Catalyst Impact 55/100 ● positive

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

Oct 19, 2026, 1:26 PM UTC · Primary ticker $RVMD

Truist Securities analyst Gregory Renza reiterated a 'Buy' rating on Revolution Medicines (RVMD) and slightly increased the price target from $240 to $241. This indicates continued analyst confidence in the company's prospects, though the minimal price target adjustment suggests no major new information or significant re-evaluation.

Truist Securities analyst Gregory Renza maintained a 'Buy' rating on Revolution Medicines (RVMD) and raised the price target from $240 to $241. This action signals continued analyst confidence in RVMD's fundamental outlook and potential for growth. While the price target increase is modest, it reinforces the positive sentiment surrounding the stock. This is primarily a short-term positive for RVMD, potentially leading to a slight uptick in investor interest or a minor price bump as the news is digested. For traders, this reiteration of a 'Buy' rating and a slightly higher price target could be seen as a confirmation of existing bullish theses, but the small magnitude of the change suggests it's not a major catalyst for significant price movement. The key opportunity for traders is to observe if this analyst action encourages broader market interest or if it's largely priced in.

$RVMD positive Analyst price target increase and 'Buy' rating reiterated
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.